Mirae Asset Global ETFs Holdings
DNLI icon

Mirae Asset Global ETFs Holdings’s Denali Therapeutics DNLI Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Sell
78,937
-16,256
-17% -$334K ﹤0.01% 1237
2026
Q1 		$1.82M Sell
95,193
-33,607
-26% -$669K ﹤0.01% 1214
2025
Q4 		$2.13M Sell
128,800
-1,087
-0.8% -$18.3K ﹤0.01% 1124
2025
Q3 		$1.89M Sell
129,887
-4,816
-4% -$69.2K ﹤0.01% 1166
2025
Q2 		$1.89M Buy
134,703
+46,196
+52% +$650K ﹤0.01% 1124
2025
Q1 		$1.21M Buy
88,507
+3,432
+4% +$65.8K ﹤0.01% 1402
2024
Q4 		$1.73M Buy
85,075
+3,411
+4% +$87.3K ﹤0.01% 1217
2024
Q3 		$2.38M Buy
81,664
+6,960
+9% +$173K 0.01% 1042
2024
Q2 		$1.73M Buy
+74,704
New +$1.43M ﹤0.01% 1147

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's DNLI Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Denali Therapeutics (DNLI) stake by 17% in Q2 2026, selling an estimated $334K and leaving 78,937 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1237.

Mirae Asset Global ETFs Holdings first reported a position in DNLI in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.38M in Q3 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 78,937 shares of Denali Therapeutics worth $2.03M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings sold 16,256 Denali Therapeutics shares in Q2 2026, an estimated $334K.
  • Denali Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1237 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Denali Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's Denali Therapeutics position peaked at $2.38M in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.